All In Biotech

Drug Trial Radar · NCT03392779

Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP1601, and the Effect of Food on ZSP1601 Pharmacokinetics

A Phase 1 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ZSP1601 and the Effect of Food on ZSP1601 Pharmacokinetics in Chinese Healthy Subjects.

Last checked: Nov 19, 2026Latest source record: Aug 13, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

94

Actual

Start

Jan 5, 2018

Primary completion

Dec 21, 2018

Study completion Mar 22, 2019

Sponsor

Sponsor type
Industry
First posted
Jan 8, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will evaluate the safety, tolerability and pharmacokinetics (PK) of escalating single- and multiple-oral doses of ZSP1601 on fasted condition, and characterize PK of ZSP1601 on an empty stomach (fasted condition) and following a high fat, high calorie meal (fed condition) in a 2-period, 2-sequence manner. The study will be conducted in 3 parts (Ascending single dose, multiple dose and food effect). Participants will receive either ZSP1601 or placebo .

Conditions

  • Nonalcoholic Steatohepatitis (NASH)

Interventions

  • ZSP1601 25 mgDrug

    ZSP1601 tablet administered orally once daily under fasted condition

  • Placebo 25mgDrug

    Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition

  • ZSP1601 50 mgDrug

    ZSP1601 tablet administered orally once daily under fasted condition

  • Placebo 50 mgDrug

    Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition

  • ZSP1601 100 mgDrug

    ZSP1601 tablets administered orally once daily in the fasting state

  • Placebo 100 mgDrug

    Participants will receive placebo matching to ZSP1601 orally once daily in the fasting state

  • ZSP1601 175 mgDrug

    ZSP1601 tablets administerekd orally once daily under fasted condition

  • Placebo 175 mgDrug

    Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition

  • ZSP1601 275 mgDrug

    ZSP1601 tablets administered orally once daily in the fasting state

  • Placebo 275 mgDrug

    Participants will receive placebo matching to ZSP1601 orally once daily in the fasting state

  • ZSP1601 350 mgDrug

    ZSP1601 tablets administered orally once daily under fasted condition

  • Placebo 350mgDrug

    Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition

  • ZSP1601 100 mgDrug

    ZSP1601 tablets administered orally once daily under fasted or fed condition

  • Placebo 100mgDrug

    Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition

  • ZSP1601 50 mgDrug

    ZSP1601 tablets administered orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).

  • Placebo 50 mgDrug

    Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).

  • ZSP1601 100 mgDrug

    ZSP1601 tablets administered orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).

  • Placebo 100 mgDrug

    Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number and severity of treatment-emergent adverse events (TEAEs) and Serious Adverse Events(SAE) following oral doses(single,multiple and food effect)of ZSP1601 and placebo.Time frame: SAD Group: Up to 4 days, MAD: Up to 17days, FE group: Up to 11 days after first dose
  2. Concomitant MedicationTime frame: UP to 4, 17, 11 days for SAD, MAD, FE part respectively
  3. Clinical Laboratory Abnormalities(Blood routine test, serum biochemical test, conventional coagulation examinations, urine examination ) post dose of ZSP1601 and placebo.Time frame: UP to 4, 17, 11 days for SAD, MAD, FE part respectively
  4. 12-lead ECG Abnormalities following oral dosing of ZSP1601 and placebo.Time frame: UP to 4, 17, 11 days for SAD, MAD, FE part respectively
  5. Vital signs Abnormalities following oral dosing of ZSP1601 and placebo.Time frame: UP to 4, 17, 11 days for SAD, MAD, FE part respectively
  6. Physical examination Abnormalities following oral dossing of ZSP1601 and placebo.Time frame: UP to 4, 17, 11 days for SAD, MAD, FE part respectively
  7. Cardiac color ultrasound(UCG) Abnormalities following multiple oral doses of ZSP1601 and placebo.Time frame: Screening, Day17

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Hospital of Jilin University

    Changchun, Jilin, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.